IGC Pharma, Inc.
IGC· NYSE
IGCIGC Pharma, Inc.
Filed Oct 16, 2018 · 10-Q · 16 days after period end · 0001185185-18-001848
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $811.00K | $235.00K | $162.16K | $2.06M |
| Net Income | -$859.00K | -$304.00K | -$583.87K | -$623.37K |
| EPS Diluted | -$0.03 | -$0.01 | -$0.02 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
ended Sep 30, 2018 · filed Oct 16, 2018 · 16 d after period end
